Logistic regression analysis of neutropenic fever in the HDMTX-P cohort
| Variable* . | OR (95% CI) . | P value . |
|---|---|---|
| Starting HDMTX on cycle 1 vs cycle ≥2 | 3.72 (1.11-12.49) | .03 |
| Age, (5-y increase) | 0.99 (0.82-1.19) | .91 |
| Age, ≥65 vs <65 y | 0.82 (0.21-3.24) | .77 |
| ECOG PS, 0-1 vs ≥2 | 0.68 (0.12-3.82) | .66 |
| LDH, elevated vs not | 1.34 (0.39-4.62) | .64 |
| Disease stage, I/II vs III/IV | 1.94 (0.33-11.54) | .47 |
| IPI, 1-unit increase | 0.85 (0.51-1.42) | .54 |
| CNS-IPI, 1-unit increase | 0.89 (0.58-1.36) | .58 |
| Number of extranodal sites, 1-unit increase | 1.08 (0.74-1.57) | .70 |
| G-CSF, administered on cycle 1 vs not | 1.43 (0.35-5.77) | .62 |
| Laboratory parameters | ||
| On day 1 of the first cycle | ||
| Albumin (g/dL), 1-unit increase | 1.13 (0.88-1.47) | .34 |
| Hemoglobin (g/dL), 1-unit increase | 0.65 (0.48-0.88) | .005 |
| Platelets (K/μL), 50-unit increase | 0.93 (0.74-1.16) | .52 |
| ANC (cells/μL), 1000-unit increase | 0.88 (0.74-1.05) | .16 |
| Creatinine clearance (mL/min), 10-unit increase | 0.93 (0.76-1.13) | .44 |
| On day 1 of the first HDMTX-containing cycle | ||
| Albumin (g/dL), 1-unit increase | 1.15 (0.90-1.46) | .26 |
| Hemoglobin (g/dL), 1-unit increase | 0.70 (0.51-0.95) | .02 |
| Platelets (K/μL), 50-unit increase | 0.85 (0.66-1.08) | .18 |
| ANC (cells/μL), 1000-unit increase | 0.89 (0.76-1.05) | .17 |
| Creatinine clearance (mL/min), 10-unit increase | 0.98 (0.86-1.12) | .74 |
| Time for methotrexate clearance in first HDMTX-containing cycle, 1-d increase | 1.11 (0.99-1.24) | .06 |
| Variable* . | OR (95% CI) . | P value . |
|---|---|---|
| Starting HDMTX on cycle 1 vs cycle ≥2 | 3.72 (1.11-12.49) | .03 |
| Age, (5-y increase) | 0.99 (0.82-1.19) | .91 |
| Age, ≥65 vs <65 y | 0.82 (0.21-3.24) | .77 |
| ECOG PS, 0-1 vs ≥2 | 0.68 (0.12-3.82) | .66 |
| LDH, elevated vs not | 1.34 (0.39-4.62) | .64 |
| Disease stage, I/II vs III/IV | 1.94 (0.33-11.54) | .47 |
| IPI, 1-unit increase | 0.85 (0.51-1.42) | .54 |
| CNS-IPI, 1-unit increase | 0.89 (0.58-1.36) | .58 |
| Number of extranodal sites, 1-unit increase | 1.08 (0.74-1.57) | .70 |
| G-CSF, administered on cycle 1 vs not | 1.43 (0.35-5.77) | .62 |
| Laboratory parameters | ||
| On day 1 of the first cycle | ||
| Albumin (g/dL), 1-unit increase | 1.13 (0.88-1.47) | .34 |
| Hemoglobin (g/dL), 1-unit increase | 0.65 (0.48-0.88) | .005 |
| Platelets (K/μL), 50-unit increase | 0.93 (0.74-1.16) | .52 |
| ANC (cells/μL), 1000-unit increase | 0.88 (0.74-1.05) | .16 |
| Creatinine clearance (mL/min), 10-unit increase | 0.93 (0.76-1.13) | .44 |
| On day 1 of the first HDMTX-containing cycle | ||
| Albumin (g/dL), 1-unit increase | 1.15 (0.90-1.46) | .26 |
| Hemoglobin (g/dL), 1-unit increase | 0.70 (0.51-0.95) | .02 |
| Platelets (K/μL), 50-unit increase | 0.85 (0.66-1.08) | .18 |
| ANC (cells/μL), 1000-unit increase | 0.89 (0.76-1.05) | .17 |
| Creatinine clearance (mL/min), 10-unit increase | 0.98 (0.86-1.12) | .74 |
| Time for methotrexate clearance in first HDMTX-containing cycle, 1-d increase | 1.11 (0.99-1.24) | .06 |
Number of events = 18.